All In Biotech

Free tool

FAERS Monitor: Luzu

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204153 or its brand name (Luzu, Luliconazole). Reports on generic versions are filed under their own applications.

Reports

176

Serious

131

74% of reports

Hospitalization

84

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective12
  • hepatic function abnormal9
  • nausea9
  • constipation8
  • pyrexia8
  • decreased appetite7
  • off label use7
  • diarrhoea6
  • pneumonia6
  • anaemia5
  • anxiety5
  • erythema5
  • sleep disorder5
  • acute kidney injury4
  • alanine aminotransferase increased4

Reports by year received

View as table
YearReports
20081
20102
20125
20132
20146
201510
201626
20176
201813
201912
20204
202111
202221
202314
202415
202518
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,983 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatic function abnormalSignal928.815.3215
sleep disorderSignal58.53.626
alanine aminotransferase increasedSignal47.83.017
constipationSignal84.42.218
decreased appetiteSignal73.61.711
anaemiaSignal53.11.35
acute kidney injury43.11.24
erythemaSignal52.91.25
pyrexiaSignal82.81.47
pneumonia62.21.03
anxiety52.10.92
nausea91.40.71
diarrhoea61.10.50
drug ineffective121.10.60
off label use71.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.